Acclaim Pharma Research, preparing to open a state-of-the-art 90-bed Phase I clinic in London, Ontario, Canada has selected LabPas CT to fully automate its clinical trials
According to Aditya Gupta, CEO and founder of Acclaim Pharma Research: "Automating our phase one trials with LabPas CT positions us on the cutting edge of the clinical trials industry.
"We offer sponsors reduced trial times, faster data lock and error-free quality".
John Rosenblum, CEO of Green Mountain Logic, which developed LabPas CT, added: "Acclaim is an exciting partner for us.
"Its commitment to quality and vision for the future is inspiring; and their strategic approach is clearly demonstrated by their newly renovated, fully automated facility".
"Our goal was to comprehensively automate our trials.
"LabPas CT was the only software that thoroughly understood the phase one environment and provided a fully integrated work flow and data management solution," said Anna Maria Di Lorenzo, director of Clinical Operations.
"We never even considered doing our trials using paper or spreadsheets".
Acclaim's new 984m2 facility is located adjacent to the University of Western Ontario, also in London, Ontario.
Acclaim Pharma Research's clinical staff has more than 25 years of pharmaceutical experience in conducting more than 85 Phase II - IV trials and 650 Phase I bioequivalence studies with extensive expertise in pharmacokinetics.
Acclaim Pharma Research is a sister company of Mediprobe Research, a Phase II - IV CRO also founded by Dr Gupta.
LabPas CT improves margins, decreases liability and increases clinical capabilities.
LabPas CT is unique in its intuitive use and adaptability to individual study protocols.
